• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2026 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Illumina Inc.

    4/9/26 4:18:50 PM ET
    $ILMN
    Medical Specialities
    Health Care
    Get the next $ILMN alert in real time by email
    DEFA14A 1 d27074ddefa14a.htm DEFA14A DEFA14A

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    SCHEDULE 14A

    Proxy Statement Pursuant to Section 14(a) of the

    Securities Exchange Act of 1934

    Filed by the Registrant ☒        Filed by a Party other than the Registrant ☐

    Check the appropriate box:

     

    ☐

    Preliminary Proxy Statement

     

    ☐

    Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ☐

    Definitive Proxy Statement

     

    ☒

    Definitive Additional Materials

     

    ☐

    Soliciting Material Under Rule 14a-12

    Illumina, Inc.

    (Name of Registrant as Specified In Its Charter)

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

    Payment

    of Filing Fee (Check all boxes that apply):

    ☒

    No fee required

     

    ☐

    Fee paid previously with preliminary materials

     

    ☐

    Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a-6(i)(1) and 0-11


    LOGO

    illumina® ILLUMINA, INC. 5200 ILLUMINA WAY SAN DIEGO, CA 92122 ATTN: CONOR MCNAMARA Your Vote Counts! ILLUMINA, INC. 2026 Annual Meeting Vote by May 20, 2026 11 :59 PM ET You invested in ILLUMINA, INC. and it’s time to vote! You have the right to vote on proposals being presented at the Annual Meeting. This is an important notice regarding the availability of proxy material for the stockholder meeting to be held on May 21, 2026. Get informed before you vote View the Notice & Proxy Statement, Form 10-K online OR you can receive a free paper or email copy of the material(s) by requesting prior to May 07, 2026. If you would like to request a copy of the material(s) for this and/or future stockholder meetings, you may (1) visit www.ProxyVote.com, (2) call 1-800-579-1639 or (3) send an email to sendmaterial@proxyvote.com. If sending an email, please include your control number (indicated below) in the subject line. Unless requested, you will not otherwise receive a paper or email copy. PV For complete information and to vote, visit www.ProxyVote.com Control # Smartphone users Point your camera here and vote without entering a control number Virtually at: Vote Virtually at the Meeting* May21,2026 10:00 AM PDT www.virtualshareholdermeeting.com/lLMN2026 *Please check the meeting materials for any special requirements for meeting attendance.


    LOGO

    Vote at www.ProxyVote.com THIS IS NOT A VOTABLE BALLOT This is an overview of the proposals being presented at the upcoming stockholder meeting. Please follow the instructions on the reverse side to vote these important matters. Voting Items Board Recommends 1 .Election of Directors Nominees: 1A Caroline D. Dorsa For 1B Scott Gottlieb, M.D. For 1C David P. King For 1D Keith A. Meister For 1 E Anna Richo For 1 F Philip W. Schiller For 1G Susan E. Siegel For 1H Jacob Thaysen, Ph.D. For 11 Scott B. Ullem For 2.To ratify the appointment of Ernst & Young LLP as our independent registered public accounting firm for the fiscal year ending January 3, 2027. For 3.To approve, on an advisory basis, the compensation of the named executive officers as disclosed in the Proxy Statement. For NOTE: Such other business as may properly come before the meeting or any adjournment thereof. You may attend the Meeting via the Internet and vote during the meeting. Have the information that is printed in the box marked with the arrow on your proxy card or Notice of Internet Availability of Proxy Materials available and follow the instructions. Prefer to receive an email instead? While voting on www.ProxyVote.com, be sure to click “Delivery Settings”.

    Get the next $ILMN alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $ILMN

    DatePrice TargetRatingAnalyst
    6/26/2026$185.00Mkt Perform
    Bernstein
    6/10/2026$185.00Neutral → Overweight
    Analyst
    5/15/2026$170.00Outperform
    RBC Capital Mkts
    5/14/2026$155.00Neutral → Outperform
    Daiwa Securities
    8/12/2025$94.00Outperform → Neutral
    Daiwa Securities
    7/11/2025$125.00Sector Outperform → Sector Perform
    Scotiabank
    3/4/2025$130.00 → $90.00Neutral
    Citigroup
    2/28/2025$100.00Buy → Hold
    HSBC Securities
    More analyst ratings

    $ILMN
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Gottlieb Scott bought $23,562 worth of shares (200 units at $117.81), increasing direct ownership by 2% to 12,723 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    2/11/26 4:04:54 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Gottlieb Scott bought $61,065 worth of shares (500 units at $122.13), increasing direct ownership by 4% to 12,523 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    11/5/25 4:05:20 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SVP, Chief Financial Officer Dhingra Ankur bought $495,381 worth of shares (6,100 units at $81.21), increasing direct ownership by 32% to 24,906 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    5/14/25 4:20:13 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    Director Meister Keith A. was granted 142 shares, increasing direct ownership by 2% to 6,780 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/26 6:25:34 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Director Ullem Scott B. was granted 167 shares, increasing direct ownership by 2% to 11,030 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    7/2/26 6:22:10 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Chief Legal Officer Davies Scott M sold $110,700 worth of shares (615 units at $180.00), decreasing direct ownership by 3% to 20,953 units (SEC Form 4)

    4 - ILLUMINA, INC. (0001110803) (Issuer)

    6/25/26 9:41:44 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Illumina expands Billion Cell Atlas program with new AI drug developers

    Partners will use unprecedented data scale to advance more precise medicines to approvalSAN DIEGO, July 16, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced that the Billion Cell Atlas alliance has added three new member companies, including AI-native drug developer Formation Bio. As leaders in AI-driven drug discovery, design, and development, alliance members will use the unprecedented scale of Illumina's genome-wide perturbation data as infrastructure for the next generation of therapeutics. "We are building the cell atlas to address key bottlenecks across the drug discovery and development continuum," said Rami Mehio, senior vice president and

    7/16/26 12:00:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

    SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's we

    7/9/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

    New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world."We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mik

    7/9/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    SEC Filings

    View All

    Illumina Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    6/23/26 9:08:49 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

    8-K - ILLUMINA, INC. (0001110803) (Filer)

    5/26/26 5:28:17 PM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SD filed by Illumina Inc.

    SD - ILLUMINA, INC. (0001110803) (Filer)

    5/19/26 4:16:55 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Bernstein resumed coverage on Illumina with a new price target

    Bernstein resumed coverage of Illumina with a rating of Mkt Perform and set a new price target of $185.00

    6/26/26 9:21:34 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina upgraded by Analyst with a new price target

    Analyst upgraded Illumina from Neutral to Overweight and set a new price target of $185.00

    6/10/26 8:16:12 AM ET
    $ILMN
    Medical Specialities
    Health Care

    RBC Capital Mkts resumed coverage on Illumina with a new price target

    RBC Capital Mkts resumed coverage of Illumina with a rating of Outperform and set a new price target of $170.00

    5/15/26 8:29:06 AM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Leadership Updates

    Live Leadership Updates

    View All

    Illumina appoints Michael Sullivan Chief Commercial Officer and Julie Coletti Chief Legal Officer

    New leaders bring extensive leadership experience across life sciences, diagnostics, and medical technologySAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Mike Sullivan as Chief Commercial Officer, effective July 20, 2026, and Julie Coletti as Chief Legal Officer, effective August 3, 2026. The appointments add experienced leaders to Illumina's Executive Leadership Team as the company continues advancing its strategy, serving customers, driving growth, and delivering on its mission to improve human health around the world."We are excited to welcome Mike and Julie to Illumina," said Jacob Thaysen, chief executive officer of Illumina. "Mik

    7/9/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    Daniel M. Skovronsky, MD, PhD, appointed to Illumina's Board of Directors

    Eli Lilly and Company's Chief Scientific and Product Officer brings pharmaceutical R&D and scientific leadership perspective to Illumina's BoardSAN DIEGO, June 23, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) today announced the appointment of Daniel M. Skovronsky, MD, PhD, to its Board of Directors, effective June 16, 2026. Dr. Skovronsky brings extensive experience in drug discovery, clinical development and translational medicine, which are areas directly relevant to Illumina's work advancing genomics and multiomics platforms. "Dan brings a rare combination of scientific expertise, innovation leadership, and healthcare

    6/23/26 9:05:00 AM ET
    $ILMN
    Medical Specialities
    Health Care

    IQM Appoints Craig Ciesla, Former Illumina VP, as CTO; Inés de Vega Becomes Chief Scientist

    Ciesla is a seasoned deep tech executive with more than 25 years of experience delivering products across industries — from startups to Fortune 500 companies. De Vega brings more than 20 years of experience advancing quantum technologies from fundamental research to intellectual property and industrial applications. IQM Quantum Computers, the global leader in superconducting quantum computers, today announced the appointments of Dr. Craig Ciesla as Chief Technology Officer (CTO) and Dr. Inés de Vega as Chief Scientist, as she transitions from her role as Vice President of Quantum Solutions, deepening IQM´s leadership as the company prepares for its planned Nasdaq listing through a me

    6/19/26 3:00:00 AM ET
    $RAAQ
    $TXG
    $ILMN
    Blank Checks
    Finance
    Biotechnology: Laboratory Analytical Instruments
    Industrials

    $ILMN
    Financials

    Live finance-specific insights

    View All

    Illumina to Announce Second Quarter 2026 Financial Results on Thursday, July 30, 2026

    SAN DIEGO, July 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the second quarter 2026 following the close of market on Thursday, July 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, July 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's we

    7/9/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina Reports Financial Results for First Quarter of Fiscal Year 2026

    SAN DIEGO, April 30, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) ("Illumina" or the "company") today announced its financial results for the first quarter of fiscal year 2026. First quarter 2026 results:Revenue of $1.09 billion for Q1 2026, up 4.8% from Q1 2025 (ROW1 organic revenue growth of 3.5%)GAAP operating margin of 19.2% and non-GAAP operating margin of 21.9%GAAP diluted EPS of $0.87 and non-GAAP diluted EPS of $1.15On April 28, 2026, our Board of Directors authorized an additional $1.5 billion in share repurchases"Illumina delivered a strong start to 2026, reflecting strength of the Illumina ecosystem and progress against our strategy," said Jacob Thaysen, Chief Executive Offic

    4/30/26 4:05:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Illumina to Announce First Quarter 2026 Financial Results on Thursday, April 30, 2026

    SAN DIEGO, April 9, 2026 /PRNewswire/ -- Illumina, Inc. (NASDAQ:ILMN) announced today that it will issue results for the first quarter 2026 following the close of market on Thursday, April 30, 2026. On the same day, at 1:30 pm Pacific Time (4:30 pm Eastern Time) Jacob Thaysen, PhD, Chief Executive Officer, and Ankur Dhingra, Chief Financial Officer, will host a conference call with analysts, investors, and other interested parties to discuss financial and operating results. Conference Call DetailsThe conference call will begin at 1:30 pm Pacific Time (4:30 pm Eastern Time) on Thursday, April 30, 2026. Interested parties may access the live webcast via the Investor Info section of Illumina's

    4/9/26 4:30:00 PM ET
    $ILMN
    Medical Specialities
    Health Care

    $ILMN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    12/6/24 10:11:24 AM ET
    $ILMN
    Medical Specialities
    Health Care

    SEC Form SC 13G filed by Illumina Inc.

    SC 13G - ILLUMINA, INC. (0001110803) (Subject)

    12/5/24 7:27:01 PM ET
    $ILMN
    Medical Specialities
    Health Care

    Amendment: SEC Form SC 13G/A filed by Illumina Inc.

    SC 13G/A - ILLUMINA, INC. (0001110803) (Subject)

    11/12/24 3:59:44 PM ET
    $ILMN
    Medical Specialities
    Health Care